About
Technology
Issues
FAQ
Links
Official Page
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.